El papel de las fracciones lipídicas, lipoproteínas y apolipoproteínas en Preeclampsia

dc.creatorSerrano Díaz, Norma Cecilia
dc.creatorAcevedo, Sandra Milena
dc.creatorOtero Motta, María Teresa
dc.creatorColmenares Mejía, Claudia Carolina
dc.creatorSepúlveda Jaime, Melisa Tatiana
dc.creatorForero Galvis, Edgar Humberto
dc.creatorRodríguez Rocha, Wiston Alberto
dc.creatorPáez Leal, María Carolina
dc.date2012-01-29
dc.identifierhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/1218
dc.identifier10.18359/rmed.1218
dc.descriptionLa Preeclampsia (PE) es un trastorno multisistémico, exclusivo de la gestación humana y responsable de aproximadamente 44.000 muertes maternas anuales a nivel mundial; esta enfermedad está asociada a múltiples complicaciones tanto en la madre como en el feto, sin embargo, su etiología no se encuentra totalmente dilucidada y en consecuencia ha sido difícil definir estrategias válidas de predicción. La PE es una enfermedad compleja y comparte diferentes factores de riesgo con las enfermedades cardiovasculares; como la obesidad, hipertensión arterial, resistencia a la insulina y dislipidemias. Con esto se evidencia que algunas alteraciones en los niveles lípidos y apolipoproteínas, se asocian con mayor peroxidación lipídica y estrés oxidativo lo cual puede desencadenar en disfunción endotelial para ambas patologías. Por tanto, la exploración de la evidencia de una asociación entre las fracciones lipídicas y riesgo de PE, puede aportar nuevo conocimiento en torno a la etiología de esta enfermedad. En la presente revisión, se plantearán las principales implicaciones biológicas de las alteraciones del perfil lipídico y apolipoproteínas en la génesis de la PE. Se describirán los estudios observacionales que se han aproximado a su evaluación y se identificarán sus principales debilidades metodológicas, con el fin de plantear estrategias para una evaluación integral de esta vía fisiopatológica, con posibles implicaciones predictivas de la enfermedad.
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad Militar Nueva Granada
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/1218/948
dc.relation/*ref*/World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Geographic Variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol. 1998; 158(1): 80-83.
dc.relation/*ref*/Khan K, Wojdyla D, Say L, Gülmezoglu A, Van Look P. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367(9516):1066–1074.
dc.relation/*ref*/Garovic V, Baileyb K, Boerwinklec E, Huntd S, Wedere A, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens. 2010; 28(4): 826–833.
dc.relation/*ref*/Girouard J, Giguère Y, Moutquin J, and Forest J. Previous Hypertensive Disease of Pregnancy Is Associated With Alterations of Markers of Insulin Resistance. Hypertension. 2007; 49(5): 1056-1062.
dc.relation/*ref*/Roberts J, Gammill H. Insulin Resistance in Preeclampsia. Hypertension. 2006; 47(3): 341-342.
dc.relation/*ref*/Poston L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep. 2006; 58Suppl: 69-74.
dc.relation/*ref*/Zavalza-Gómez AB. Obesity and oxidative stress: a direct link to preeclampsia? Arch Gynecol Obstet. 2011; 283(3): 415-422.
dc.relation/*ref*/Redman CWG, Sargent IL. Placental debris, oxidative stress and preeclampsia. Placenta.2000; 21(7): 597–602.
dc.relation/*ref*/Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365(9461): 785-799.
dc.relation/*ref*/Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003; 361(9368): 1511-1517.
dc.relation/*ref*/Murphy BP, Stanton T, Dunn FG. Hypertension and myocardial ischemia. Med Clin North Am. 2009; 93(3): 681-695.
dc.relation/*ref*/Cnossen JS, Leeflang MM, de Haan EE, Mol BW, van der Post JA, Khan KS, et al. Accuracy of body mass index in predicting pre-eclampsia: bivariate meta-analysis. BJOG. 2007; 114(12): 1477-1485.
dc.relation/*ref*/Berg LH. Lipid measurements for coronary risk assessment: a review. Am J Med Technol. 1981; 47(7): 539-543.
dc.relation/*ref*/Francis KT. HDL cholesterol and coronary heart disease. South Med J. 1980; 73(2): 169-173.
dc.relation/*ref*/Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988; 8(1): 1-21.
dc.relation/*ref*/Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 372(9635): 1829-1839.
dc.relation/*ref*/Enquobahrie DA, Williams MA, Butler CL, Frederick IO, Miller RS, Luthy DA. Maternal plasma lipid concentrations in early pregnancy and risk of preeclampsia. Am J Hypertens. 2004; 17(7): 574-581.
dc.relation/*ref*/Belo L, Caslake M, Gaffney D, Santos-Silva A, Pereira-Leite L, Quintanilha A, et al. Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis. 2002; 162(2): 425-432. 19. Bayhan G, Koçyigit Y, Atamer A, Atamer Y, Akkus Z. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia. GynecolEndocrinol. 2005; 21(1): 1-6.
dc.relation/*ref*/Koçyigit Y, Atamer Y, Atamer A, Tuzcu A, Akkus Z. Changes in serum levels of leptin, cytokines and lipoprotein in preeclamptic and normotensive pregnant women. GynecolEndocrinol. 2004;19(5): 267-273.
dc.relation/*ref*/Rodie VA, Caslake MJ, Stewart F, Sattar N, Ramsay JE, Greer IA, Freeman DJ. Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies com- plicated by pre-eclampsia and intrauterine growth restriction. Atherosclerosis. 2004; 176(1): 181-187.
dc.relation/*ref*/Barden AE, Beilin LJ, Ritchie J, Walters BN, Michael C. Does a predisposition to the metabolic syndrome sensitize women to develop pre-eclampsia? J Hypertens. 1999; 17(9): 1307-1315.
dc.relation/*ref*/Wakatsuki A, Ikenoue N, Okatani Y, Shinohara K, Fukaya T. Lipoprotein particles in preeclampsia: susceptibility to oxidative modification. Obstet Gynecol. 2000; 96(1): 55-59.
dc.relation/*ref*/Raijmakers MT, van Tits BJ, Hak-Lemmers HL, Roes EM, Steegers EA, Peters WH. Low plasma levels of oxidized low density lipoprotein in preeclampsia. Acta Obstet Gynecol Scand. 2004; 83(12): 1173-1177.
dc.relation/*ref*/Vanderjagt DJ, Patel RJ, El-Nafaty AU, Melah GS, Crossey MJ, Glew RH. High-density lipoprotein and homocysteine levels correlate inversely in preeclamptic women in northern Nigeria. ActaObstetGynecol Scand. 2004; 83(6): 536-542.
dc.relation/*ref*/Ware-Jauregui S, Sanchez SE, Zhang C, Laraburre G, King IB, Williams MA. Plasma lipid concentrations in pre-eclamptic and normotensive Peruvian women. Int J Gynaecol Obstet. 1999; 67(3): 147-155.
dc.relation/*ref*/Powers RW, Evans RW, Majors AK, Ojimba JI, Ness RB, Crombleholme WR, Roberts JM. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol. 1998; 179(6 PT 1): 1605-1611.
dc.relation/*ref*/Vadachkoria S, Woelk GB, Mahomed K, Qiu C, Muy-Rivera M, Malinow MR, Williams MA. Elevated soluble vascular cell adhesion molecule-1, elevated Homocyst(e)inemia, and hypertriglyceridemia in relation to preeclampsia risk. Am J Hypertens. 2006; 19(3): 235-242.
dc.relation/*ref*/Clausen T, Djurovic S, Henriksen T. Dyslipidemia in early second trimester is mainly a feature of women with early onset pre-eclampsia. BJOG. 2001; 108(10): 1081-1087.
dc.relation/*ref*/Kaaja R, Tikkanen MJ, Viinikka L, Ylikorkala O. Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women. Obstet Gynecol. 1995; 85(3): 353-356.
dc.relation/*ref*/Maseki M, Nishigaki I, Hagihara M, Tomoda Y, Yagi K. Lipid peroxide levels and lipids content of serum lipoprotein fractions of pregnant subjects with or without pre-eclampsia. ClinChimActa. 1981; 115(2): 155-161.
dc.relation/*ref*/Gratacós E, Casals E, Sanllehy C, Cararach V, Alonso PL, Fortuny A. Variation in lipid levels during pregnancy in women with different types of hypertension. ActaObstetGynecol Scand. 1996; 75(10):896-901. 33. Williams MA, Woelk GB, King IB, Jenkins L, Mahomed K. Plasma carotenoids, retinol, tocopherols, and lipoproteins in preeclamptic and normotensive pregnant Zimbabwean women. Am J Hypertens. 2003; 16(8):665-672.
dc.relation/*ref*/Murai JT, Muzykanskiy E, Taylor RN. Maternal and fetal modulators of lipid metabolism correlate with the development of preeclampsia. Metabolism. 1997; 46(8):963-967.
dc.relation/*ref*/Baker AM, Klein RL, Moss KL, Haeri S, Boggess K. Maternal serum dyslipidemia occurs early in pregnancy in women with mild but not severe preeclampsia. Am J Obstet Gynecol. 2009; 201(3): 293.e1-4.
dc.relation/*ref*/Mayret-Mesquiti M, Pérez-Méndez O, Rodríguez ME, Fortoul TI, Gorocica P, Bernal-Alcántara D, Montaño LF, Alvarado- Vasquez N. Hypertriglyceridemia is linked to reduced nitric oxide synthesis in women with hypertensive disorders of pregnancy. Hypertens Pregnancy. 2007; 26(4): 423-431.
dc.relation/*ref*/Franz H, Wendler D. A controlled study of maternal serum concentrations of lipoproteins in pregnancy-induced hypertension. Arch Gynecol Obstet. 1992; 252(2): 81-86.
dc.relation/*ref*/Llurba E, Casals E, Domínguez C, Delgado J, Mercadé I, Crispi F, Martín-Gallán P, Cabero L, Gratacós E. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. Metabolism. 2005; 54(11): 1504-1509.
dc.relation/*ref*/Oqura K, Miyatake T, Fukui O, Nakamura T, Kameda T, Yoshino G. Low-density lipoprotein particle diameter in normal pregnancy and preeclampsia. J AtherosclerThromb. 2002; 9(1): 42-47.
dc.relation/*ref*/Hubel CA, Lyall F, Weissfeld L, Gandley RE, Roberts JM. Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metabolism. 1998; 47(10): 1281-1288.
dc.relation/*ref*/Catarino C, Rebelo I, Belo L, Rocha-Pereira P, Rocha S, Castro EB, Patrício B, Quintanilha A, Santos-Silva A. Fetal lipoprotein changes in pre-eclampsia. Acta Obstet Gynecol Scand. 2008; 87(6): 628-634.
dc.relation/*ref*/Yamaguchi K. Triglycerides and apoproteins in toxemia of pregnancy. Nihon SankaFujinkaGakkaiZasshi. 1988; 40(12): 1875-1882.
dc.relation/*ref*/Sanchez SE, Zhang C, Williams MA. The influence of maternal triglyceride levels on infant birth weight in Peruvian women with pre-eclampsia. J Matern Fetal Neonatal Med. 2003; 13(5): 328-333.
dc.relation/*ref*/Mikhail MS, Basu J, Palan PR, Furgiuele J, Romney SL, Anyaegbunam A. Lipid profile in women with preeclampsia:relationship between plasma triglyceride levels and severity of preeclampsia. J Assoc Acad Minor Phys. 1995; 6(1): 43-45.
dc.relation/*ref*/Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith G, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ. 2007; 10; 335(7627): 978.
dc.relation/*ref*/McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S; INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008 19; 372(9634): 224-233.
dc.relation/*ref*/Zhang H, Zhang Y, Yang F, Li L, Liu S, Xu Z, Wang J, Sun S. Complement component C4A and apolipoprotein A-I in plasmas as biomarkers of the severe, early-onset preeclampsia. Mol Biosyst. 2011; 7(8): 2470-2479.
dc.relation/*ref*/Koçyigit Y, Atamer Y, Atamer A, Tuzcu A, Akkus Z. Changes in serum levels of leptin, cytokines and lipoprotein in preeclamptic and normotensive pregnant women. Gynecol Endocrinol. 2004; 19(5): 267-273.
dc.relation/*ref*/Belo L, Gaffney D, Caslake M, Santos-Silva A, Pereira-Leite L, Quintanilha A, Rebelo I. Apolipoprotein E and cholesteryl ester transfer protein polymorphisms in normal and preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol. 2004; 112(1): 9-15.
dc.relation/*ref*/Var A, Kucu NK, Koyuncu F, Uyanik BS, Onur E, Yildirim Y, Oruç S. Atherogenic profile in preeclampsia. Arch Gynecol Obstet. 2003; 268(1): 45-47.
dc.relation/*ref*/Hayman RG, Sattar N, Warren AY, Greer I, Johnson IR, Baker PN. Relationship between myometrial resistance artery behavior and circulating lipid composition. Am J Obstet Gynecol. 1999; 180(2 Pt 1): 381-386.
dc.relation/*ref*/Kobayashi S, Tanaka M, Masaki K, Hirakawa S, Momose K. Apolipoprotein levels in preeclamptic pregnancies. Nihon SankaFujinkaGakkaiZasshi. 1992; 44(2): 223-228.
dc.relation/*ref*/Rosing U, Samsioe G, Olund A, Johansson B, Kallner A. Serum levels of apolipoprotein A-I, A-II and HDL-cholesterol in second half of normal pregnancy and in pregnancy complicated by pre-eclampsia. HormMetab Res. 1989; 21(7):376-382
dc.relation/*ref*/Demir B, Demir S, Atamer Y, Guven S, Atamer A, Kocyigit Y, Hekimoglu A, Toprak G. Serum levels of lipids, lipoproteins and paraoxonase activity in pre-eclampsia. J Int Med Res. 2011; 39(4): 1427-1431.
dc.relation/*ref*/Lei Q, Lv LJ, Zhang BY, Wen JY, Liu GC, Lin XH, Niu JM. Ante-partum and post-partum markers of metabolic syndrome in pre-eclampsia. J Hum Hypertens. 2011; 25(1): 11-17.
dc.relation/*ref*/Sarandöl E, Safak O, Dirican M, Uncu G. Oxidizability of apolipoprotein B-containing lipoproteins and serum paraoxonase/ arylesterase activities in preeclampsia. ClinBiochem. 2004; 37(11): 990-996.
dc.relation/*ref*/Cekmen MB, Erbagci AB, Balat A, Duman C, Maral H, Ergen K, Ozden M, Balat O, Kuskay S. Plasma lipid and lipoprotein concentrations in pregnancy induced hypertension. ClinBiochem. 2003; 36(7): 575-578.
dc.relation/*ref*/Winkler K, Wetzka B, Hoffmann MM, Friedrich I, Kinner M, Baumstark MW, Zahradnik HP, Wieland H, März W. Triglyceride- rich lipoproteins are associated with hypertension in preeclampsia. J ClinEndocrinolMetab. 2003; 88(3): 1162-1666.
dc.relation/*ref*/Bai H, Liu X, Liu R, Liu Y, Li M, Liu B. Analysis of serum lipid and apolipoprotein levels in pregnancy-induced hypertension and normotensive pregnant women. Hua Xi Yi Ke Da XueXueBao. 2002; 33(1): 58-61.
dc.relation/*ref*/Bartha JL, Comino-Delgado R, Bedoya FJ, Barahona M, Lubian D, Garcia-Benasach F. Maternal serum nitric oxide levels associated with biochemical and clinical parameters in hypertension in pregnancy. Eur J ObstetGynecolReprod Biol. 1999; 82(2): 201-207.
dc.relation/*ref*/Chalas J, Audibert F, Francoual J, Le Bihan B, Frydman R, Lindenbaum A. Concentrations of apolipoproteins E, C2, and C3 and lipid profile in preeclampsia. Hypertens Pregnancy. 2002; 21(3): 199-204.
dc.relation/*ref*/Carty D, Delles C, Dominiczak A. Novel Biomarkers for Predicting Preeclampsia. Trends Cardiovasc Med. 2008; 18(5): 186–194.
dc.relation/*ref*/Nagy B, Rigo J, Fintor L, Romics L, Papp Z, et al. Distribution of Apolipoprotein(a) Isoforms in Normotensive and Severe Preeclamptic Women. J Matern Fetal Med 1999; 8(6):270–274.
dc.relation/*ref*/Henriksen T. The role of lipid oxidation and lipid oxidative derivatives in the development of preeclampsia. SeminPerinatol. 2000; 24(1): 29-32.
dc.relation/*ref*/Atamer Y, Koçyigit Y, Yokus B, Atamer A, Erden AC. Lipid peroxidation, antioxidant defense, status of trace metals and leptin levels in preeclampsia. Eur J ObstetGynecolReprod Biol. 2005; 119(1):60-66.
dc.relation/*ref*/Raijmakers MT, Peters WH, Steegers EA, Poston L. NAD(P)H oxidase associated superoxide production in human placenta from normotensive and pre-eclamptic women. Placenta. 2004; Suppl A: S85-89.
dc.relation/*ref*/Dowhan W, Bodanov H. Functional roles of lipids in membranes. Biochemistry of Lipids, Lipoproteins and Membranes, 4th ed. Vance DE, Vance JE, editors. Elsevier; 2002.
dc.relation/*ref*/Murray RK, Granner DK, Rodwell VW. Lipids of physiologic significance. Harper’s illustrated biochemistry. 27th ed. Papadakis MA, Mcphee SJ,editores. McGraw-Hill Companies, Inc.; 2006.
dc.relation/*ref*/Gratacos E, Asals E, Nllehy A, Cararach V, Alonso P et al. Variation in lipid levels during pregnancy in women with different types of hypertension. ActaObsteGynecol Scand 1996; 75(10): 896-901.
dc.relation/*ref*/Takacs P, Kauma S, Sholley M, Walsh S, Dinsmoor J , Green K. Increased circulating lipid peroxides in severe preeclampsia activate NF-κB and upregulate ICAM-1 in vascular endothelial cells. The FASEB. 2001; 15(2):279-281.
dc.relation/*ref*/Hubel C. Oxidative stress in pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999;222(3): 222-235.
dc.relation/*ref*/McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008; 372(9634): 224-233
dc.relation/*ref*/Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007; 298(11): 1300-1311.
dc.relation/*ref*/Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003; 32(1): 1-22
dc.relation/*ref*/Keavney B. Genetic epidemiological studies of coronary heart disease. Int J Epidemiol. 2002; 31(4):730-736.
dc.relation/*ref*/Smith GD, Phillips AN. Confounding in epidemiological studies: why “independent” effects may not be all they seem. BMJ. 1992; 305(6836): 757-759.
dc.relation/*ref*/Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and the risk of cardiovascular disease and cancer in later life: a systematic review and meta-analysis. BMJ. 2007; 335(7627): 974.
dc.relation/*ref*/Morgan TH. Heredity and sex. New York:Columbia University Press;1913: 27.
dc.relation/*ref*/Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003; 32(1):1-22.
dc.relation/*ref*/Keavney B. Genetic epidemiological studies of coronary heart disease. Int J Epidemiol. 2002; 31(4): 730-736.
dc.relation/*ref*/Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361(9360): 865-872
dc.relation/*ref*/Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004; 33(1): 30-42.
dc.relation/*ref*/Hingorani A, Humphries S. Nature’s randomised trials. Lancet. 2005; 366(9501): 1906-1908.
dc.relation/*ref*/Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomization. Lancet 2005; 365(9455): 224-232.
dc.relation/*ref*/Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a metaanalysis. JAMA 2002; 288(16): 2023-2031. 86. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 2006; 35(4): 922-931.
dc.relation/*ref*/Hingorani AD, Shah T, Casas JP. Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk. Eur Heart J. 2006; 27(11):1331-1337.
dc.relation/*ref*/Brunner EJ, Kivimäki M, Witte DR, Lawlor DA, Davey Smith G, Cooper JA, et al. Inflammation, insulin resistance, and diabetes - Mendelian randomization using CRP haplotypes points upstream. PLoS Med. 2008; 12(5): e155.
dc.rightsDerechos de autor 2015 Revista Med
dc.sourceRevista Med; Vol. 20 No. 1 (2012): january - june; 62-73
dc.sourceRevista Med; Vol. 20 Núm. 1 (2012): enero - junio; 62-73
dc.source1909-7700
dc.source0121-5256
dc.subjectpreeclampsia
dc.subjectdislipidemias
dc.subjectapolipoproteínas
dc.subjectperoxidación lipídica
dc.subjectanálisis de randomización mendeliana
dc.titleEl papel de las fracciones lipídicas, lipoproteínas y apolipoproteínas en Preeclampsia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución